Werewolf Therapeutics (NASDAQ:HOWL) has been analyzed by 4 analysts in the last three months, revealing a diverse range of ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $7.25, a high ...

Lyra Therapeutics stock is falling hard with heavy trading on Monday after the company reported a failed Phase 3 clinical ...

AXSM stock results show that Axsome Therapeutics beat analyst estimates for earnings per share and beat on revenue for the ...

NDAQ:AKRO) The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors ...

Pittsburgh-based biotech firm NeuBase Therapeutics, which is in the process of dissolving, will be removed from the Nasdaq ...

Good morning and welcome to the Axsome Therapeutics conference call. Currently, all participants are in a listen-only mode.

By Colin Kellaher Lyra Therapeutics shares collapsed to an all-time low on Monday after the clinical-stage biotechnology company reported the failure of ...

Summit Therapeutics specializes in developing innovative therapeutic solutions for oncology and infectious diseases. Their ...

By Colin Kellaher Lyra Therapeutics on Monday said a late-stage study of its lead drug candidate missed its main goal in a chronic inflammatory ...

SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to ...

Lyra Therapeutics shares are trading lower by 93% to $0.30 during Monday's session. The company announced the ENLIGHTEN 1 ...